Faculty

Faculty

Blanca Ledezma

MSN, NP, AOCNP

Department of Hematology Oncology Santa Monica, California

UCLA Health

Faculty

Marissa Marti-Smith

DNP, APRN, AGNP-C, AOCNP

Texas Oncology-Baylor Charles A Sammons Cancer Center, Dallas, Texas

Nurse Practitioner

Faculty

Ruth M O'Regan, MD

University of Rochester Medical Center, Rochester, New York

Charles A Dewey Professor of Medicine and Oncology, Chair, Department of Medicine,

Strong Memorial Hospital, Rochester, New York

Physician-in-Chief

Wilmot Cancer Institute, Rochester, New York

Associate Director of Education and Mentoring

Moderator

Heather McArthur

MD, MPH, FASCO

UT Southwestern Medical Center, Dallas, Texas

Professor, Department of Internal Medicine, Clinical Director, Breast Cancer Program, Komen Distinguished Chair in Clinical Breast Cancer Research

Program Schedule — Central Time

5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 7:30 PM — Educational Meeting

MODULE 1: Biology and Current Management of Hormone-Receptor (HR)-Positive Metastatic Breast Cancer (mBC); Clinical Relevance of ESR1 Mutations

• Incidence, pathophysiology and clinical characteristics of HR-positive mBC
• Current role of endocrine-based therapies in the management of HR-positive mBC; known mechanisms of resistance to hormonal therapy
• Prevalence of ESR1 mutations in HR-positive, HER2-negative mBC; relevance of prior therapeutic exposure
• Optimal timing and approach to testing for ESR1 mutations in patients with HR-positive, HER2-negative mBC
• Role of oncology nurses in facilitating assessment for ESR1 status in patients with HR-positive, HER2-negative mBC and in helping them understand the implications of results

MODULE 2: Current Role of Oral Selective Estrogen Receptor Degraders (SERDs) in Therapy for HR-Positive mBC

• Mechanistic similarities and differences between fulvestrant and the various available and investigational oral SERDs; implications for efficacy and tolerability
• Published efficacy outcomes with elacestrant for patients with progressive HR-positive, HER2-negative mBC
• Major findings documenting the efficacy of imlunestrant monotherapy for patients with pretreated HR-positive, HER2-negative mBC
• FDA approvals of elacestrant and imlunestrant for patients with previously treated HR-positive, HER2-negative mBC and ESR1 mutations
• Identification of patients appropriate for treatment with elacestrant or imlunestrant

MODULE 3: Potential Role of Early Therapeutic Switching from an Aromatase Inhibitor to an Oral SERD After Detection of an Emergent ESR1 Mutation During First-Line Therapy for HR-Positive mBC

• Early-phase data with camizestrant alone for previously treated HR-positive, HER2-negative advanced breast cancer
• Biological rationale for and potential benefit of serial ESR1 testing for patients receiving first-line endocrine therapy
• Design, eligibility criteria and key efficacy and safety findings from the Phase III SERENA-6 study evaluating a switch from an aromatase inhibitor to camizestrant after detection of an emergent ESR1 mutation during first-line therapy for HR-positive, HER2-negative mBC
• Potential role of serial ESR1 testing and early therapeutic switching for patients found to harbor ESR1 mutations

MODULE 4: Potential Role of Combination Approaches with Oral SERDs for HR-Positive, HER2-Negative Breast Cancer

• Biological rationale for combining oral SERDs with other systemic therapies, such as CDK4/6 inhibitors or PI3K/AKT/mTOR inhibitors
• Efficacy and safety outcomes documented with imlunestrant/abemaciclib for patients with HR-positive, HER2-negative advanced breast cancer with and without ESR1 mutations
• Recently presented data comparing giredestrant in combination with everolimus to standard endocrine therapy with everolimus for pretreated HR-positive, HER2-negative mBC
• Potential role of oral SERD-containing combination regimens and identification of patients appropriate for this approach
• Ongoing assessments of other oral SERD-based strategies for patients with HR-positive breast cancer

MODULE 5: Tolerability of Currently Approved and Investigational Oral SERDs

• Spectrum, frequency and severity of common class-effect toxicities, such as gastrointestinal (GI) side effects, musculoskeletal pain, fatigue and myelosuppression, documented with oral SERDs; comparative tolerability of elacestrant and imlunestrant
• Recommended prophylaxis, monitoring and management of GI toxicities associated with oral SERDs
• Pathophysiology of hyperlipidemia observed with elacestrant and imlunestrant; optimal lipid-profile monitoring for patients receiving either agent
• Incidence and severity of anemia and hypocalcemia noted with imlunestrant versus other oral SERDs; appropriate monitoring for and management of laboratory-value abnormalities in patients receiving these agents

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Appreciate the incidence and clinical implications of ESR1 mutations in endocrine-resistant metastatic breast cancer (mBC), and determine optimal strategies to effectively identify patients harboring these abnormalities.
• Understand the biological rationale for, mechanism of action of and pharmacologic similarities and differences among available and investigational oral selective estrogen receptor degraders (SERDs).
• Interrogate published research documenting the efficacy of oral SERD monotherapy in patients with hormone receptor (HR)-positive, HER2-negative mBC with ESR1 mutations who experience disease progression on standard endocrine therapy in combination with a CDK4/6 inhibitor, in order to optimally understand the role of these agents in patient care.
• Review available research findings with serial ESR1 testing using ctDNA as a means to inform early therapeutic switching for patients with HR-positive mBC receiving CDK4/6 inhibitor-based first-line therapy, and consider the clinical applicability of this novel strategy.
• Evaluate available clinical trial data with oral SERDs in combination with other systemic therapies, such as CDK4/6 inhibitors or mTOR inhibitors, and consider the potential role of these regimens.
• Appreciate side effects associated with available and investigational oral SERDs, and use this information to develop supportive management plans for patients receiving this form of therapy.
• Assess ongoing clinical research evaluating novel applications of oral SERDs for HR-positive breast cancer, and counsel patients regarding the potential benefits of trial participation.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/OralSERDsMetastaticBreastCancer/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Ms Ledezma — Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Lilly, Pfizer Inc; Steering Committees: AstraZeneca Pharmaceuticals LP. Dr Marti-Smith — Consulting Agreements: Amplity; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, A Hologic Company, Daiichi Sankyo Inc, Stemline Therapeutics Inc; Nonrelevant Financial Relationships: ASCO Quality Care Symposium, Clinical Care Options, Kaplan, OncLive, Oncology Nursing News. Dr O’Regan — Advisory Committees: Biotheranostics Inc, A Hologic Company; Consulting Agreements: Biotheranostics Inc, A Hologic Company, Gilead Sciences Inc, Lilly, Puma Biotechnology Inc, Regor Pharmaceuticals; Contracted Research: Novartis, Puma Biotechnology Inc; Data and Safety Monitoring Boards/Committees: Gilead Sciences Inc.

MODERATOR — Dr McArthur — Advisory Committees: Arvinas, AstraZeneca Pharmaceuticals LP, Boston Scientific Corporation, Celcuity, Daiichi Sankyo Inc, Delcath Systems Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, Novartis, Pfizer Inc; Consulting Agreements: ALX Oncology.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP, Lilly, and Stemline Therapeutics Inc.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.